Asked by: Bell Ribeiro-Addy (Labour - Clapham and Brixton Hill)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the answer of 12 November 2025 to Question 87400 on Prosthetics and Wigs: Ethnic Groups, whether he will make an assessment of the impact of limited access to suitable breast prosthesis on those patients.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Jim McMahon (Labour (Co-op) - Oldham West, Chadderton and Royton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what was the cost to the public purse of installing new telephone systems in GP practices in England last year; and how many (a) systems (b) handsets were installed.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the proportion of written parliamentary questions which receive answers within within the usual time period.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Charlotte Cane (Liberal Democrat - Ely and East Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 17 November 2025 to Question 77307, on Cancer: Health Services, how his Department intends to support businesses and organisations based in the Ely and East Cambridgeshire constituency to develop cancer research programmes.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer research as one of the largest areas of spend, at over £141.6 million in 2024/25, signalling its high priority.
The NIHR Research Support Service (RSS) provides expert support and advice to applied health, public health, and social care researchers on the design and delivery of research and the development of research funding applications. This is a national service and researchers based in the Ely and East Cambridgeshire constituency who are applying to national, open and peer-reviewed research programmes, including all domestic NIHR funding programmes, UK Research Councils, and national health and care charities, can access this support. Further information on the RSS is available at the following link:
https://www.nihr.ac.uk/support-and-services/research-support-service
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancer types. Applications are subject to peer review and judged in open competition.
Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to stop the illicit (a) manufacturing, (b) importation and (c) sale of (i) counterfeit and (ii) unlicensed weight-loss drugs.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicines for human use, medical devices, and blood products for transfusion in the United Kingdom. This includes applying the legal controls on the retail sale, supply, and advertising of medicines which are set out in the Human Medicines Regulations 2012.
Many authorised weight loss medicines are prescription-only, meaning that a consultation with a doctor or qualified healthcare professional is needed to assess the patient's suitability for the treatment and to consider any potential risks. Usually, such products should only be obtained from a registered pharmacy against a valid prescription.
Sourcing weight loss medicines from unregulated suppliers significantly increases the risk of getting a product which is either falsified or not authorised for use. Products purchased in this way will not meet the MHRA’s strict quality and safety standards and could expose patients to incorrect dosages or dangerous ingredients.
Public safety is the number one priority for the MHRA, and its Criminal Enforcement Unit works hard to prevent, detect, and investigate illegal activity involving medicines and medical devices, and it takes robust enforcement action where necessary. It works closely with other health regulators, customs authorities, law enforcement agencies, and private sector partners, including e-commerce and the internet industry, to identify, remove, and block online content promoting the illegal sale of medicines and medical devices.
The MHRA seeks to identify and, where appropriate, prosecute online sellers responsible for putting public health at risk. Last year, the MHRA and its partners seized more than 17 million doses of illegally traded medicines, including those usually issued on prescription. A recent example of our enforcement activity is available at the following link:
Additionally, the MHRA has also disrupted thousands of links to websites and social media pages selling medical products to the public illegally.
The MHRA’s FakeMeds campaign provides advice to people in the UK who are considering buying medication online, outlining how products can be accessed from safe and legitimate source. Further information on the FakeMeds campaign is available at the following link:
https://fakemeds.campaign.gov.uk/
Anyone who believes they’ve had a side effect from a medicine, or think they’ve received falsified stock, can report it to the MHRA’s Yellow Card scheme, with further information available at the following link:
https://yellowcard.mhra.gov.uk/
Asked by: Andy MacNae (Labour - Rossendale and Darwen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Civil Procedure Rule Committee on the implementation of fixed recoverable costs in clinical negligence claims valued up to £25,000.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.
As announced in the recently published 10-Year Health Plan for England, David Lock KC will be providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims, ahead of a review by the Department in the autumn.
The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the Medicines and Healthcare products Regulatory Agency has spent on translation and interpretation services in each of the last five years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department which regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy. The following table shows how much the MHRA has spent on translation and interpretation services in each of the last five years:
Year | Translation | Sign language | Total |
2020/21 | £521.86 | £1,554.00 | £2,075.86 |
2021/22 | £9,725.01 | £648.00 | £10,373.01 |
2022/23 | £796.24 | £1,050.00 | £1,846.24 |
2023/24 | - | £3,138.00 | £3,138.00 |
2024/25 | £355.60 | £2,275.20 | £2,630.80 |
Total | £11,398.71 | £8,665.20 | £20,063.91 |
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve helipad access at hospitals in the Midlands Air Ambulance region.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Air ambulances form a vital part of the emergency response to patients in critical need. The Department of Health and Social Care continues to work closely with NHS England and the Department for Transport on helipad accessibility for air ambulances across the country including the Midlands.
Asked by: Richard Holden (Conservative - Basildon and Billericay)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 November 2025 to Question 87431 on Congenital Abnormalities, what use is made of consanguinity data collected by NHS England through the Maternity Services Data Set in (a) regional public health planning, (b) genetic counselling services and (c) maternal and neonatal clinical risk assessments; and if he will publish any guidance issued to Integrated Care Boards which either references or is a result of that data.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Bell Ribeiro-Addy (Labour - Clapham and Brixton Hill)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 November 2025 to Question 87401 on Prosthetics and Wigs: Ethnic Groups, whether he will ensure that there is guidance or a requirement for NHS Trusts to procure breast prosthesis and wigs which meet the diverse needs of their patients, beyond the availability of such products through the NHS Supply Chain frameworks.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.